Ticker LaunchFiled, not priced
EIR Biopharma, Inc.
EIR Biopharma, Inc. publicly filed a registration statement on Form S-1 on Feb 17, 2026 for a proposed initial public offering on NYSE American, and has not yet priced. The filing shows a price range of $4.00–$5.00 per share. Underwriters named in the filing: Kingswood.
EIR Biopharma, Inc. is an early-stage biopharmaceutical company developing therapeutics for eye disease. Its strategy is to negotiate worldwide exclusive licenses for the right to develop such therapies, targeting preclinical and clinical candidates.
- Status
- Filed, not priced
- Exchange
- NYSE American
- Price range
- $4.00–$5.00
- First filed
- Feb 17, 2026
- Latest amendment
- Feb 17, 2026
- Underwriters
- Kingswood
- Sector
- Biotech & pharma
- Country / state
- CA
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Feb 17, 2026
- Latest amendment Feb 17, 2026
- All filings on EDGAR CIK 1966774
Other companies in the IPO pipeline
- Medical 21, Inc.Feb 19, 2026
- Hacker Interstellar Inc.Feb 13, 2026
- Solar Strategy Holdings LtdFeb 13, 2026
- Beta FinTech Holdings LtdFeb 12, 2026
- Hong qi bang bang kai man science & technology development Co., LtdFeb 11, 2026
- Xiamen Customized Elf Technology Co., Ltd.Feb 11, 2026